1. Home
  2. NBN vs PHAT Comparison

NBN vs PHAT Comparison

Compare NBN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northeast Bank

NBN

Northeast Bank

HOLD

Current Price

$108.69

Market Cap

933.4M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$10.58

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBN
PHAT
Founded
1872
2018
Country
United States
United States
Employees
234
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
933.4M
894.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NBN
PHAT
Price
$108.69
$10.58
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$117.50
$19.50
AVG Volume (30 Days)
94.0K
940.4K
Earning Date
04-28-2026
04-30-2026
Dividend Yield
0.04%
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$13.77
$92.15
Revenue Next Year
$18.72
$59.79
P/E Ratio
$11.29
N/A
Revenue Growth
N/A
216.93
52 Week Low
$78.17
$2.21
52 Week High
$126.26
$18.31

Technical Indicators

Market Signals
Indicator
NBN
PHAT
Relative Strength Index (RSI) 46.08 43.50
Support Level $104.40 $10.06
Resistance Level $112.94 $12.62
Average True Range (ATR) 3.66 0.67
MACD 0.31 0.08
Stochastic Oscillator 42.78 35.00

Price Performance

Historical Comparison
NBN
PHAT

About NBN Northeast Bank

Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: